This clinical trial is focused on studying a condition called Hereditary Angioedema (HAE), which is a rare genetic disorder that causes sudden swelling in various parts of the body, such as the face, hands, and feet. The study is testing a new treatment called NTLA-2002, which is designed to help manage and reduce the frequency of these swelling attacks. NTLA-2002 is a special type of treatment that uses advanced technology involving nucleic acids, which are the building blocks of genetic material. This treatment is given through an infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the safety and effectiveness of NTLA-2002 in adults with Hereditary Angioedema. The study is divided into different phases. In the first phase, the main goal is to determine the safety of NTLA-2002 and find the right dose for further testing. In the second phase, the focus is on understanding how well NTLA-2002 can reduce the number of HAE attacks. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of NTLA-2002. There is also a part of the study where participants who initially received a placebo or a lower dose of NTLA-2002 may receive a higher dose to further assess safety.

Participants in the study will receive the treatment through an intravenous infusion, which means it is administered directly into a vein. The study will monitor participants over a period of time to observe any changes in the frequency of HAE attacks and to ensure the treatment is safe. The study aims to provide valuable information that could lead to better management of Hereditary Angioedema in the future.